Most Read Articles
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
Roshini Claire Anthony, 22 Sep 2020

Treatment with the DPP 1* inhibitor brensocatib prolonged time to exacerbation and reduced exacerbation rates in patients with non-cystic fibrosis bronchiectasis, according to the phase II WILLOW** study presented at ERS 2020.

Audrey Abella, 22 Sep 2020
The first-in-class oral tyrosine kinase inhibitor (TKI) masitinib demonstrated a positive benefit-risk profile over a sustained period in patients with severe persistent asthma regardless of baseline eosinophil level, with the greatest benefit seen among those with the highest oral corticosteroid (OCS) dependency, according to data presented at ERS 2020.
Audrey Abella, 05 Oct 2020
Regular, low-dose, oral sustained-release morphine improved the health status of patients with moderate-to-very-severe chronic breathlessness due to chronic obstructive pulmonary disease (COPD), the MORDYC* trial has shown, validating its palliative role for chronic breathlessness.

Poor pulmonary function implicated in dementia

11 Feb 2020

Poor pulmonary function, particularly in midlife, may contribute to an increased risk of later dementia, as suggested in the results of a meta-analysis.

Researchers searched multiple online databases for studies linking pulmonary function or respiratory illness to incident dementia using the following keywords: dementia, Alzheimer, forced expiratory volume (FEV), forced vital capacity (FVC), peak expiratory flow (PEF), asthma, COPD, respiratory disease, lung disease and pneumonia, among others.

The search yielded 20 studies for inclusion in the meta-analysis: 10 studies reported pulmonary function and 11 did respiratory illness (one study reported both pulmonary function and respiratory illness).

Pooled data revealed the lowest vs highest quartile of FEV in one second (FEV1) conferred a 1.4-fold greater dementia risk (hazard ratio [HR], 1.46, 95 percent confidence interval [CI], 0.77–2.75; p=0.092; I2, 69.3 percent; n=62,209; two studies).

Furthermore, every 1-standard deviation decrease in FEV1 was associated with a 28-percent risk increase (HR, 1.28, 95 percent CI, 1.03–1.60; p=0.028; I2, 78.2 percent; n=67,505; six studies).

Respiratory illness also showed a similar magnitude of association with dementia risk (HR, 1.54, 95 percent CI, 1.30–1.81; p<0.001; I2, 92.4 percent; n=288,641; 11 studies). These associations were observed across different countries and research groups, in both men and women, and persisted despite adjustments for a range of confounding factors.

The researchers underscored a need for further investigation to establish whether or not the association between pulmonary function and cognition might reflect a cause-and-effect relation.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Respirology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
Roshini Claire Anthony, 22 Sep 2020

Treatment with the DPP 1* inhibitor brensocatib prolonged time to exacerbation and reduced exacerbation rates in patients with non-cystic fibrosis bronchiectasis, according to the phase II WILLOW** study presented at ERS 2020.

Audrey Abella, 22 Sep 2020
The first-in-class oral tyrosine kinase inhibitor (TKI) masitinib demonstrated a positive benefit-risk profile over a sustained period in patients with severe persistent asthma regardless of baseline eosinophil level, with the greatest benefit seen among those with the highest oral corticosteroid (OCS) dependency, according to data presented at ERS 2020.
Audrey Abella, 05 Oct 2020
Regular, low-dose, oral sustained-release morphine improved the health status of patients with moderate-to-very-severe chronic breathlessness due to chronic obstructive pulmonary disease (COPD), the MORDYC* trial has shown, validating its palliative role for chronic breathlessness.